Decarbonisation in pharma and healthcare: State of the sector 2025 report

Our State of the Sector 2025 report maps the decarbonisation commitment of 25 leading pharmaceutical companies, 17 key collaborations, and renewable energy markets across 7 regions.

This first-of-its-kind sectorial landscape helps companies and collaborations benchmark progress, align efforts, and cut through the complexity:

• All 25 companies have Scope 1 & 2 targets; over two-thirds aim for near-term reductions by 2030
• Scope 3 targets are growing, but vary widely in ambition and structure
• Supplier engagement is essential, but often complex, inconsistent, and unsupported
• Collaborations are everywhere, but risk overlap and supplier fatigue
• Data management is fragmented, creating a burden for suppliers
• Renewable energy markets are maturing but not equally across regions
• Standardising product footprinting remains a major unmet need

Uncover how leading companies are advancing climate goals, where the challenges remain, and how multi-stakeholder partnerships and renewable energy sourcing accelerate positive impact.

Download the full report here:

---

State of the Sector 2025

About the methodology:

Our research is based entirely on publicly available data for 25 of the world’s largest pharmaceutical companies, 17 collaborative initiatives, and 7 key energy markets. Data was cross-checked and initiative profiles were shared for narrative review, ensuring editorial accuracy while preserving independent analysis.